title: Platelet function in dogs: breed differences and effect of acetylsalicylic acid administration.
abstract: BACKGROUND
  Clinical studies investigating platelet function in dogs have had conflicting results that may be caused by normal physiologic variation in platelet response to agonists.
  
  
  OBJECTIVE
  The objective of this study was to investigate platelet function in clinically healthy dogs of 4 different breeds by whole-blood aggregometry and with a point-of-care platelet function analyzer (PFA-100), and to evaluate the effect of acetylsalicylic acid (ASA) administration on the results from both methods.
  
  
  METHODS
  Forty-five clinically healthy dogs (12 Cavalier King Charles Spaniels [CKCS], 12 Cairn Terriers, 10 Boxers, and 11 Labrador Retrievers) were included in the study. Platelet function was assessed by whole-blood aggregation with ADP (1, 5, 10, and 20 microM) as agonist and by PFA-100 using collagen and epinephrine (Col + Epi) and Col + ADP as agonists. Plasma thromboxane B(2) concentration was determined by an enzyme immunoassay. To investigate the effect of ASA, 10 dogs were dosed daily (75 or 250 mg ASA orally) for 4 consecutive days.
  
  
  RESULTS
  A higher platelet aggregation response was found in CKCS compared to the other breeds. Longer PFA-100 closure time (Col + Epi) was found in Cairn Terriers compared to Boxers. Plasma thromboxane B(2) concentration was not statistically different between groups. Administration of ASA prolonged the PFA-100 closure times, using Col + Epi (but not Col + ADP) as agonists. Furthermore, ASA resulted in a decrease in whole-blood platelet aggregation.
  
  
  CONCLUSIONS
  Platelet function is influenced by breed, depending upon the methodology applied. However, the importance of these breed differences remains to be investigated. The PFA-100 method with Col + Epi as agonists, and ADP-induced platelet aggregation appear to be sensitive to ASA in dogs.
authors.affiliation: Department of Animal and Veterinary Basic Sciences, Faculty of Life Sciences, University of Copenhagen, Frederiksberg, Denmark. lini@novozymes.com
authors.forename: Line A
authors.initials: LA
authors.lastname: Nielsen
authors.forename: Nora E
authors.initials: NE
authors.lastname: Zois
authors.forename: Henrik D
authors.initials: HD
authors.lastname: Pedersen
authors.forename: Lisbeth H
authors.initials: LH
authors.lastname: Olsen
authors.forename: Inge
authors.initials: I
authors.lastname: Tarnow
mesh_terms: D000818:Animals; D001241:Aspirin / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology*; D002478:Cells, Cultured; D004285:Dogs / Q000145:classification* / Q000235:genetics / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006262:Health; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D019095:Point-of-Care Systems